(Q73104089)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11042564%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

title

Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma. The ONCOPAZ Cooperative Group (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11042564%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

main subject

phase II clinical trial

1 reference

J Feliu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11042564%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

M P López Alvarez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11042564%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

M A Jaraiz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11042564%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

M Constenla

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11042564%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

J M Vicent

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11042564%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

J Belón

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11042564%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

L López Gómez

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11042564%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

J de Castro

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11042564%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

J Dorta

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11042564%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

M González Barón

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11042564%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

language of work or name

English

0 references

publication date

1 October 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11042564%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11042564%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

volume

89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11042564%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11042564%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

1706-1713

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11042564%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

cites work

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

Practical recommendations for the management of adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

Chemotherapy prolongs survival in inoperable pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

Continuous 5-fluorouracil (5FU) infusion in carcinoma of the pancreas: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

A phase II survival comparison of patients with adenocarcinoma of the pancreas treated with 5-fluorouracil and calcium leucovorin versus a matched tumor registry control population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

One-sample multiple testing procedure for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

Should further studies of chemotherapy be carried out in pancreatic cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

No standard treatment is available for advanced pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

Report on nationwide pooled data and cohort investigation in UFT phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820001015%2989%3A8%3C1706%3A%3AAID-CNCR9%3E3.0.CO%3B2-I

10.1002/1097-0142(20001015)89:8<1706::AID-CNCR9>3.0.CO;2-I

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11042564%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference